EUVIMEDEUVIMED entdecken
Crossref

Drug–drug interaction study with itraconazole supplemented with physiologically based pharmacokinetic modelling to characterize the effect of CYP3A inhibitors on venglustat pharmacokinetics

Li Li iD, Yan-Yan Zhang, Jyoti Sharma, Sylvaine Cartot-Cotton, Nigel Crawford, Sreeraj Macha, Yi Li, Jasminder Sahi

British Journal of Clinical Pharmacology · 2025

DOI: 10.1002/bcp.70037 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Clinical Pharmacology, 2025. Verfasst von Li Li und 7 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacokinetics, Dynamics and Metabolism, Sanofi, Shanghai, China. Hauptthemen laut MEDLINE: Itraconazole, Cytochrome P-450 CYP3A Inhibitors, Models, Biological. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 22 Literaturangaben. Gefördert von: Sanofi.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Venglustat is an oral glucosylceramide synthase inhibitor under clinical investigation to treat various lysosomal storage diseases. Metabolism is a main pathway for its elimination in humans with CYP3A being the major contributor. This study aims to evaluate effect of CYP3A inhibition (using itraconazole) on venglustat exposure and to develop and validate a physiologically based pharmacokinetic (PBPK) model to assess effects of additional CYP3A inhibitors of varying potencies on venglustat pharmacokinetics.

Methods

An open‐label, single‐sequence, 2‐period drug–drug interaction (DDI) study was conducted in healthy subjects with coadministration of multiple twice daily oral doses of 100 mg itraconazole against a single dose of 15 mg venglustat. A minimal PBPK model was developed using available physicochemical, in vitro and in vivo pharmacokinetic data and validated using data from relevant venglustat clinical studies including the itraconazole DDI study. Effects of additional CYP3A inhibitors on venglustat exposure were predicted.

Results

Coadministration with itraconazole increased venglustat area under the concentration–time curve by 2.03‐fold (90% confidence interval [90%CI]: 1.81–2.27). Venglustat steady‐state area under the concentration–time curve during a dosing interval following coadministration with strong (clarithromycin), moderate (fluconazole) and weak (fluvoxamine and cimetidine; with CYP2D6 inhibition turned off) CYP3A inhibitors is predicted to increase by 1.74‐ (5th–95th centile, 1.30–2.49), 1.52‐ (1.23–1.88), 1.08‐ (1.03–1.15) and 1.08‐fold (1.04–1.12), respectively.

Conclusion

The effect of itraconazole on venglustat exposure was quantified clinically, and a minimal PBPK model was successfully developed, validated and applied to assess DDI effect of additional CYP3A inhibitors on venglustat. The results help to further understand the DDI potential with venglustat and will inform dose recommendations with comedications.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ItraconazoleCytochrome P-450 CYP3A InhibitorsModels, BiologicalHumansDrug InteractionsAdultMaleYoung AdultCytochrome P-450 CYP3AFemaleHealthy VolunteersMiddle AgedArea Under CurveGlucosyltransferasesAdministration, Oral

Stichwörter der Autor:innen

PBPKdrug–drug interactionvenglustat

Substanzen

ItraconazoleCytochrome P-450 CYP3A InhibitorsCytochrome P-450 CYP3AGlucosyltransferasesceramide glucosyltransferase

Autor:innen und Institutionen

  • Pharmacokinetics, Dynamics and Metabolism, Sanofi, Shanghai, China.
  • Pharmacokinetics, Dynamics and Metabolism, Sanofi, Bridgewater, New Jersey, USA.
  • Pharmacokinetics, Dynamics and Metabolism, Sanofi, Vitry-sur-Seine, France.
  • Translational Medicine and Clinical Pharmacology, Sanofi, Bridgewater, New Jersey, USA.
  • Oncology development, Sanofi, Bridgewater, New Jersey, USA.
  • Pharmacokinetics, Dynamics and Metabolism, Sanofi, Cambridge, Massachusetts, USA.

ORCID-Profile: Li Li

Förderung

  • Sanofi

Zitieren

APA

Li, L., Zhang, Y. Y., Sharma, J., Cartot-Cotton, S., Crawford, N., Macha, S., Li, Y., & Sahi, J. (2025). Drug–drug interaction study with itraconazole supplemented with physiologically based pharmacokinetic modelling to characterize the effect of CYP3A inhibitors on venglustat pharmacokinetics. British Journal of Clinical Pharmacology. https://doi.org/10.1002/bcp.70037

Vancouver

Li L, Zhang YY, Sharma J, Cartot-Cotton S, Crawford N, Macha S, et al. Drug–drug interaction study with itraconazole supplemented with physiologically based pharmacokinetic modelling to characterize the effect of CYP3A inhibitors on venglustat pharmacokinetics. British Journal of Clinical Pharmacology. 2025. doi:10.1002/bcp.70037

BibTeX
@article{Li2025,
  author = {Li, Li and Zhang, Yan-Yan and Sharma, Jyoti and Cartot-Cotton, Sylvaine and Crawford, Nigel and Macha, Sreeraj and Li, Yi and Sahi, Jasminder},
  title = {Drug–drug interaction study with itraconazole supplemented with physiologically based pharmacokinetic modelling to characterize the effect of CYP3A inhibitors on venglustat pharmacokinetics},
  journal = {British Journal of Clinical Pharmacology},
  year = {2025},
  doi = {10.1002/bcp.70037}
}
Kostenlos starten →